Navigation Links
Neurocrine Biosciences Reports Third Quarter 2013 Results
Date:10/29/2013

e and Boehringer Ingelheim during 2012, as scheduled.

Research and development expenses were $9.5 million during the third quarter of 2013 compared to $9.9 million for the same period in 2012. For the nine months ended September 30, 2013, research and development expenses were $30.3 million, compared to $28.1 million for the same period last year. The increase in year-to-date research and development expenses is primarily due to increased external development costs related to the Company's VMAT2 program (NBI-98854) as it continues through Phase IIb clinical development.

Updated 2013 Financial GuidanceThe Company expects to end 2013 with approximately $145 million in cash, investments and receivables. The net loss for 2013 is expected to be approximately $46 to $47 million, or approximately $0.70 loss per share based on 67 million basic common shares outstanding. The previous financial guidance for 2013 was a net loss of $50 to $55 million with year-end cash, investments and receivables exceeding $130 million.

Pipeline HighlightsElagolix UpdateAbbVie is currently conducting the Violet Petal Study, a Phase III study of elagolix for endometriosis. The study is a 24-week, multinational, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 875 women, age 18 to 49, with moderate to severe endometriosis-associated pain. Approximately 160 sites in the United States, Puerto Rico and Canada are conducting this study.

AbbVie recently initiated the second Phase III study of elagolix for endometriosis. This study is similar in design to the Violet Petal Study and will assess 788 women, age 18 to 49, with moderate to severe endometriosis-associated pain at more than 200 sites globally.AbbVie is also currently conducting a Phase IIb study of elagolix in uterine fibroids. This study is assessing uterine blood los
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Reports Second Quarter 2013 Results
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
5. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
6. Neurocrine Biosciences Reports Third Quarter 2012 Results
7. Neurocrine Biosciences Reports Second Quarter 2012 Results
8. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
9. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
10. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
11. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 Biofertilizers stimulate microbial activities in ... and phosphorous through the activities in the soil or ... due to the stress on reducing environmental pollution and ... report defines and segments the bio fertilizers market with ...
(Date:1/22/2015)... COLUMBIA, Md. (PRWEB) January 22, 2015 ... of its new UV-1280 multipurpose UV-visible spectrophotometer. Offering ... compact, high-quality instrument is ideal for applications in ... and life science. , The user-friendly UV-1280 enables ...
(Date:1/22/2015)... (PRWEB) January 21, 2015 Cambridge Semantics, the ... technology, today announced that 2014 was a record-breaking year across ... capabilities of the Anzo Smart Data Platform and our Smart ... utilize insights from diverse data which led to record growth ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... PLYMOUTH MEETING, Pa., Nov. 5 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: ... the Company plans to release third quarter 2009 financial results ... The Company will hold a conference call ... quarter 2009 results. Listeners may access the call by,dialing ...
... This webinar, ... continuous flow chemistry processing, will deal with the application of the ReactIR flow cell inline ... 670 publications has been recognized with several prestigious prizes and awards, including most recently the ... Columbia, ...
... , ROCKVILLE, Md., Nov. 4 ... next-generation antibody drug development, today announced that it has ... Enterprise Associates (NEA), one of the world,s leading venture ... novel, multi-specific antibody-like molecules that address two or more ...
Cached Biology Technology:BMP Sunstone to Report Third Quarter 2009 Financial Results 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 3Zyngenia, Inc. Raises $10 Million in Series A Funding 2Zyngenia, Inc. Raises $10 Million in Series A Funding 3Zyngenia, Inc. Raises $10 Million in Series A Funding 4
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 31U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... led by Nancy Rabalais, Ph.D., from the Louisiana Universities Marine ... Mexico dead zone to be smaller than forecasted, measuring 3,000 ... to water just above the sea floor, was severe where ... in most years. Earlier this summer, NOAA-sponsored forecast ...
... system in the developing nervous system is linked to smaller ... to movement, memory and emotion, according to new research led ... published in the August issue of the journal Nature ... as cerebellar interneurons are targeted for DNA damage and are ...
... 2009) Crack open the latest medical textbook to the ... hard pressed to find the term "immunology" anywhere. This is ... exceptions, distant cousins. However, a group of papers ... from Harvard Medical School researchers, have linked type 2 diabetes ...
Cached Biology News:Smaller than expected, but severe, dead zone in Gulf of Mexico 2Scientists track impact of DNA damage in the developing brain 2Scientists track impact of DNA damage in the developing brain 3Common allergy drug reduces obesity and diabetes in mice 2Common allergy drug reduces obesity and diabetes in mice 3Common allergy drug reduces obesity and diabetes in mice 4
... Caspase-9 Pan-Caspase In Situ Assay Kit, Fluorescein ... active caspases in cells undergoing apoptosis. The ... for use in diagnostic or therapeutic procedures. ... use a novel approach to detect active ...
... silencing experiments often call for critical, ... Transfection Agent refines siRNA transfection protocols ... lipid-based formulation can be used to ... are subcultured without increased cytotoxicity. ...
... as well as other yeasts, has become ... laboratories. The ability to transform whole cells ... DNAs using lithium based buffers and polyethylene ... library screening easy and reliable, especially when ...
...
Biology Products: